Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Archives of Dermatological Research
Erschienen in: Archives of Dermatological Research 5/2016

11.03.2016 | Review

Interleukin-33: increasing role in dermatological conditions

verfasst von: Anna Balato, Annunziata Raimondo, Nicola Balato, Fabio Ayala, Serena Lembo

Erschienen in: Archives of Dermatological Research | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Interleukin-33 is a novel and an unconventional member of IL-1 family. It is an inflammation-induced factor with dual function exercising its role as an intracellular regulator of gene expression, as well as, an extracellular alarm mediator. It is a ligand for ST2, a heterodimeric membrane-bound receptor of the orphan IL-1 family receptor. Interleukin-33/ST2 signaling has been studied in a wide range of inflammatory skin conditions for its crucial role in immune responses and tissue homeostasis. In this review, we report the current knowledge regarding the complex biology of interleukin-33 and its function in the skin and in clinical settings.
Literatur
1.
Ali S, Mohs A, Thomas M (2011) The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol 187:1609–1616CrossRefPubMed
2.
Bae S, Kang T, Hong J et al (2012) Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity. J Biol Chem 287:8205–8213CrossRefPubMedPubMedCentral
3.
Baekkevold ES, Roussigne M, Yamanaka T et al (2003) Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163:69–79CrossRefPubMedPubMedCentral
4.
Balato A, Lembo S, Mattii M et al (2012) IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 21:892–894CrossRefPubMed
5.
Balato A, Di Caprio R, Canta L et al (2014) IL-33 is regulated by TNF-α in normal and psoriatic skin. Arch Dermatol Res 306:299–304CrossRefPubMed
6.
7.
Bourgeois E, Van LP, Samson M et al (2009) The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 39:1046–1055CrossRefPubMed
8.
Bulek K, Swaidani S, Qin J et al (2011) The essential role of single Ig IL-1 receptor-related molecule Toll IL-1R8 in regulation of Th2 immune response. J Immunol 182:2601–2609CrossRef
9.
Byrne SN, Beaugie C, O’Sullivan C et al (2011) The immune-modulating cytokine and endogenous alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am J Pathol 179:211–222CrossRefPubMedPubMedCentral
10.
Carmi-Levy I, Homey B, Soumelis V (2011) A modular view of cytokine networks in atopic dermatitis. Clin Rev Allergy Immunol 41:245–253CrossRefPubMed
11.
Carriere V, Roussel L, Ortega N et al (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin associated nuclear factor in vivo. Proc Natl Acad Sci USA 104:282–287CrossRefPubMed
12.
13.
Chan WL, Pejnovic N, Lee CA et al (2001) Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol 167:1238–1244CrossRefPubMed
14.
Choi YS, Park JA, Kim J et al (2012) Nuclear IL-33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation. Biochem Biophys Res Commun 421:305–311CrossRefPubMed
15.
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550CrossRefPubMed
16.
Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Rev Drug Discov 11:633–652CrossRef
17.
Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I et al (2009) IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 183:1446–1455CrossRefPubMed
18.
Garlanda C, Riva F, Polentarutti N et al (2004) Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 101:3522–3526CrossRefPubMedPubMedCentral
19.
Garlanda C, Anders HJ, Mantovani A (2009) TIR8_SIGIRR: an IL-1R_TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 30:439–446CrossRefPubMed
20.
21.
22.
Guarneri F, Minciullo PL, Mannucci C et al (2015) IL-31 and IL-33 circulating levels in allergic contact dermatitis. Eur Ann Allergy Clin Immunol 47:156–158PubMed
23.
Guo L, Wei G, Zhu J et al (2009) IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci USA 106:13463–13468CrossRefPubMedPubMedCentral
24.
Homey B, Steinhoff M, Ruzicka T, Leung DY (2006) Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 118:178–189CrossRefPubMed
25.
Hueber AJ, Alves-Filho JC, Asquith DL et al (2011) IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 41:2229–2237CrossRefPubMed
26.
Imai Y, Yasuda K, Sakaguchi Y et al (2013) Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 110:13921–13926CrossRefPubMedPubMedCentral
27.
Iwahana H, Yanagisawa K, Ito-Kosaka A et al (1999) Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 264:397–406CrossRefPubMed
28.
Kakinuma T, Wakugawa M, Nakamura K et al (2003) High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br J Dermatol 148:203–210CrossRefPubMed
29.
Kakkar R, Hei H, Dobner S, Lee RT (2012) Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 287:6941–6948CrossRefPubMedPubMedCentral
30.
Kasperkiewicz M, Zillikens D (2007) The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 33:67–77CrossRefPubMed
31.
Kay AB, Clark P, Maurer M et al (2015) Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria. Br J Dermatol 172:1294–1302CrossRefPubMed
32.
Komai-Koma M, Gilchrist DS, McKenzie ANJ et al (2011) IL-33 activates B1 cells and exacerbates contact sensitivity. J Immunol 186:2584–2591CrossRefPubMed
33.
Kondo Y, Yoshimoto T, Yasuda K et al (2008) Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 20:791–800CrossRefPubMed
34.
Kurowska-Stolarska M, Stolarski B, Kewin P et al (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 183:6469–6477CrossRefPubMed
35.
Langley NJ (1906) On nerve endings and on special excitable substances in cells. Proc R Soc Lond Ser B 78:170CrossRef
36.
Lefrancais E, Roga S, Gautier V et al (2012) IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA 109:1673–1678CrossRefPubMedPubMedCentral
37.
Li P, Ma H, Han D, Mou K (2015) Interleukin-33 affects cytokine production by keratinocytes in Vitiligo. Clin Exp Dermatol 40:163–170CrossRefPubMed
38.
39.
Lowes MA, Kikuchi T, Fuentes-Duculan J et al (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128:1207–1211CrossRefPubMed
40.
Luthi AU, Cullen SP, McNeela EA et al (2009) Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31:84–98CrossRefPubMed
41.
Manetti M, Ibba-Manneschi L, Liakouli V et al (2010) The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 69:598–605CrossRefPubMed
42.
Manetti M, Guiducci S, Ceccarelli C et al (2011) Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis 70:1876–1878CrossRefPubMed
43.
Mantovani A, Sica A, Sozzani S et al (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677–686CrossRefPubMed
44.
Mattii M, Ayala F, Balato N et al (2013) The balance between pro- and anti-inflammatory cytokines is crucial in human allergic contact dermatitis pathogenesis: the role of IL-1 family members. Exp Dermatol 22:813–819CrossRefPubMed
45.
Mayuzumi N, Matsushima H, Takashima A (2009) IL-33 promotes DC development in BM culture by triggering GMCSF production. Eur J Immunol 39:3331–3342CrossRefPubMedPubMedCentral
46.
McGuirk P, McCann C, Mills KH (2002) Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 195:221–231CrossRefPubMedPubMedCentral
47.
Meephansan J, Tsuda H, Komine M et al (2012) Regulation of IL-33 expression by IFN-γ and tumor necrosis factor-α in normal human epidermal keratinocytes. J Invest Dermatol 132:2593–2600CrossRefPubMed
48.
Meephansan J, Komine M, Tsuda H et al (2013) Expression of IL-33 in the epidermis: the mechanism of induction by IL-17. J Dermatol Sci 71:107–114CrossRefPubMed
49.
Miniati A, Weng Z, Zhang B et al (2012) Neuro-immuno-endocrine processes in vitiligo pathogenesis. Int J Immunopathol Pharmacol 25:1–7PubMed
50.
Mitsui A, Tada Y, Takahashi T et al (2015) Serum IL-33 levels are increased in patients with psoriasis. Clin Exp Dermatol (epub ahead of print)
51.
Moussion C, Ortega N, Girard JP (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS ONE 3:e3331CrossRefPubMedPubMedCentral
52.
O’Neill LA (2008) The interleukin-1 receptor Toll-like receptor superfamily: 10 years of progress. Immunol Rev 226:10–18CrossRefPubMed
53.
Ohno T, Oboki K, Kajiwara N et al (2009) Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 183:7890–7897CrossRefPubMed
54.
Onda H, Kasuya H, Takakura K et al (1999) Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 19:1279–1288CrossRefPubMed
55.
Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y (2002) ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 299:18–24CrossRefPubMed
56.
Palmer G, Gabay C (2011) Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 7:321–329CrossRefPubMed
57.
Pecaric-Petkovic T, Didichenko SA, Kaempfer S et al (2009) Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113:1526–1534CrossRefPubMedPubMedCentral
58.
Puxeddu I, Italiani P, Giungato P et al (2013) Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria. Cytokine 61:741–743CrossRefPubMed
59.
Rank MA, Kobayashi T, Kozaki H et al (2009) IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 123:1047–1054CrossRefPubMedPubMedCentral
60.
Rankin AL, Mumm JB, Murphy E et al (2010) IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 184:1526–1535CrossRefPubMed
61.
Rho SS, Park H, Kim YM, Kwon YG, Colotta F, Re F, Muzio M et al (1993) Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261:472–475CrossRef
62.
Roussel L, Erard M, Cayrol C, Girard JP (2008) Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 9:1006–1012CrossRefPubMedPubMedCentral
63.
Ryu WI, Lee H, Kim JH et al (2015) IL-33 induces Egr-1-dependent TSLP expression via the MAPK pathways in human keratinocytes. Exp Dermatol (epub ahead of print)
64.
Saint-Mezard P, Berard F, Dubois B et al (2004) The role of CD4+ and CD8+ T cells in contact hypersensitivity and allergic contact dermatitis. Eur J Dermatol 14:131–138PubMed
65.
Salimi M, Barlow JL, Saunders SP et al (2013) A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 210:2939–2950CrossRefPubMedPubMedCentral
66.
Savinko T, Matikainen S, Saarialho-Kere U et al (2012) IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol 132:1392–1400CrossRefPubMed
67.
Savinko T, Karisola P, Lehtimäki S et al (2013) ST2 regulates allergic airway inflammation and T-cell polarization in epicutaneously sensitized mice. J Invest Dermatol 133:2522–2529CrossRefPubMed
68.
Schmitz J, Owyang A, Oldham E et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490CrossRefPubMed
69.
Seltmann J, Roesner LM, von Hesler FW et al (2015) IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol 135:1659–1661CrossRefPubMed
70.
Silver MR, Margulis A, Wood N et al (2010) IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 59:207–218CrossRefPubMed
71.
Smithgall MD, Comeau MR, Yoon BR et al (2008) IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 20:1019–1030CrossRefPubMed
72.
Sundnes O, Pietka W, Loos T et al (2015) Epidermal expression and regulation of interleukin-33 during homeostasis and inflammation: strong species differences. J Invest Dermatol 135:1771–1780CrossRefPubMed
73.
Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G (2009) Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 284:19420–19426CrossRefPubMedPubMedCentral
74.
Talabot-Ayer D, McKee T, Gindre P et al (2012) Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 79:32–37CrossRefPubMed
75.
Tamagawa-Mineoka R, Okuzawa Y, Masuda K, Katoh N (2014) Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol 70:882–888CrossRefPubMed
76.
Taniguchi K, Yamamoto S, Hitomi E et al (2013) Interleukin 33 is induced by tumor necrosis factor alpha and interferon gamma in keratinocytes and contributes to allergic contact dermatitis. J Investig Allergol Clin Immunol 23:428–434PubMed
77.
Theoharides TC, Zhang B, Kempuraj D et al (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107:4448–4453CrossRefPubMedPubMedCentral
78.
van der Meer JW, Barza M, Wolff SM, Dinarello CA (1988) A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA 85:1620–1623CrossRefPubMedPubMedCentral
79.
Wakatabi K, Mayumi K, Meephansan J et al (2012) The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid. Eur J Dermatol 22:333–336PubMed
80.
Wollheim FA (2005) Classification of systemic sclerosis. Visions and reality. Rheumatology 44:1212–1216CrossRefPubMed
81.
Yanaba K, Yoshizaki A, Asano Y et al (2011) Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 30:825–830CrossRefPubMed
82.
Yang Q, Yu C, Yang Z et al (2014) Deregulated NLRP3 and NLRP1 inflammasomes and their correlations with disease activity in systemic lupus erythematosus. J Rheumatol 41:444–452CrossRefPubMed
83.
Yuan L, Yao L, Zhao L et al (2013) Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 31:428–432PubMed
84.
Zhao Q, Chen G (2014) Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. Biomed Res Int 2014:587376PubMedPubMedCentral
Metadaten
Titel
Interleukin-33: increasing role in dermatological conditions
verfasst von
Anna Balato
Annunziata Raimondo
Nicola Balato
Fabio Ayala
Serena Lembo
Publikationsdatum
11.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 5/2016
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-016-1638-7

Weitere Artikel der Ausgabe 5/2016

Archives of Dermatological Research 5/2016 Zur Ausgabe

Original Paper

Functional testing of topical skin formulations using an optimised ex vivo skin organ culture model

Original Paper

Development and validation of the Patient Benefit Index for the dermatocosmetic treatment of aged skin

Original Paper

Anti-melanogenic effects of resveratryl triglycolate, a novel hybrid compound derived by esterification of resveratrol with glycolic acid

Original Paper

Reflectance confocal microscopy for scarring and non-scarring alopecia real-time assessment

Concise Communication

High prevalence of specific KIR types in patients with HHV-8 positive cutaneous vascular lesions: a possible predisposing factor?

Original Paper

S100A8/A9 is an important host defence mediator in neuropathic foot ulcers in patients with type 2 diabetes mellitus

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

16.04.2024 | DGIM 2024 | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

12.04.2024 | Vitiligo | Nachrichten

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt
weitere anzeigen

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise